Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Community delivery of medication of transport services, community health workers, all of these services are currently still impacted", Christine Stegling, deputy executive director of UNAIDS, told ...

Q4 2024 Earnings Conference Call February 7, 2025 3:00 AM ETCompany ParticipantsNicolas Hieronimus - CEOChristophe Babule ...

On Wednesday, Recursion announced favorable efficacy data in the Phase II trial for REC-994, the company’s lead AI-derived candidate ... University of Utah in the lab of Dean Li, MD, PhD.

KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present ...

But another finding also caught the investigators’ attention: Laboratory data available from ... anemia in all women of reproductive age could lead to risk reduction and improved maternal ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...